期刊文献+

放疗增敏剂在老年食管癌放疗中的疗效评价 被引量:2

Curative effect evaluation of radiation sensitizing agents in elderly patients with esophageal carcinoma treated by radiotherapy
下载PDF
导出
摘要 目的分析放疗增敏剂在老年食管癌放疗中的疗效及不良反应。方法随机将74例不能或拒绝手术的食管癌患者分为单纯放疗组及放疗加增敏剂组。放疗均采用三维适形放疗,靶区剂量60~66GY,放疗增敏组每周3次于放疗前半小时内静点甘氨双唑1.25g。结果单放组完全缓解(CR)11例,部分缓解(PR)11例,稳定(NR)及进展(PD)15例,有效率为59.5%(22/37);增放组完全缓解(CR)20例,部分缓解(PR)10例,稳定(NR)及进展(PD)7例,有效率为81.1%(30/37)。单放组及增放组1、2、3年生存率分别为40.5%(15/37)、18.9%(7/37)、5.4%(2/37)及70.3%(26/37)、40.5%(15/37)、29.7%(11/37)。两组生存率比较,差异有统计学意义(P<0.01)。静点增敏剂后无明显不良反应。结论对于那些不能手术,或因多种原因拒绝手术的老年食管癌患者,加增敏剂放疗是其一种行之有效的方法 ,且无明显不良反应,其远期疗效尚有待进一步研究。 Objective To analyze the efficacy and side effects of radiation sensitizing agents in elderly patients with esophageal carcinoma treated by radiotherapy.Methods A retrospective review was carried out in 74 cases with esophageal cancer fail or refuse to operation were randomly divided into pure radiotherapy and radiotherapy sensitizer group.All patients were given three-dimensional conformal radiotherapy,and the target dose was 60-66 GY.Radiotherapy group was given glycididazole 1.25 g intravenous within half an hour before treatment 3 times a week.Results In radiation group,11 cases were complete response (CR),11 cases were partial response (PR),15 cases were no response or progressive disease (NR+PD),with an efficiency of 59.5% (22/37).In sensitizer group,20 cases were complete response (CR),10 cases were partial response (PR),7 cases were no response or progressive disease (NR+PD),with an efficiency of 81.1% (30/37).1,2,3 years survival rates of radiation group and sensitizer group were 40.5% (15/37),18.9% (7/37),5.4% (2/37) and 70.3% (26/37),40.5% (15/37),29.7% (11/37) respectively.There was no obvious adverse reaction in sensitizer group.Conclusion Radiotherapy adds sensitizing agents is effective for patients with esophageal carcinoma who fail or refuse to accept surgery.It has no obvious adverse reaction,but its long-term efficacy remains to be further studied.
作者 李晓红
出处 《中国当代医药》 2012年第30期102-103,共2页 China Modern Medicine
关键词 老年食管癌 放射治疗 增敏剂 疗效 elderly patients with esophageal cancer Radiotherapy Sensitizer Effect
  • 相关文献

参考文献9

二级参考文献15

共引文献182

同被引文献44

  • 1祝淑钗,李任,李娟,邱嵘,韩春,万钧.非手术治疗胸段食管癌临床分期与预后关系的初步探讨[J].中华放射肿瘤学杂志,2004,13(3):189-192. 被引量:70
  • 2张力建.老年性食管癌的诊治现状[J].中华老年多器官疾病杂志,2005,4(3):172-174. 被引量:21
  • 3Akutsu Y, Shuto K, Kono T, et al. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepatogastroenterology. 2012;59(119): 2095-2098. 被引量:1
  • 4Fencl P, Belohlavek O, Harustiak T, et al. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012; 33(11) 1188-1194. 被引量:1
  • 5Ji Y, Zheng MF, Ye SG, et al. Agrocybe aegerita polysaccharide combined with chemotherapy improves tumor necrosis factor-a and interferon-~ levels in rat esophageal carcinoma. Dis Esophagus. 2013;26(8):859- 863. 被引量:1
  • 6Kobayashi N, Nakayama H, Osaka Y, et al. Tumor response after 10w-dose preoperative radiotherapy combined with chemotherapy for squamous cell esophageal carcinoma. Anticancer Res. 2013;33(3):1157-1161. 被引量:1
  • 7Choi N, Park SD, Lynch T, et al. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Int J Radiat Oncol Biol Phys. 2004;60(1):111-122. 被引量:1
  • 8Kim MK, Cho K J, Park SI, et al. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(1):115-121. 被引量:1
  • 9Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. Oncology 2013;84(5):305-310. 被引量:1
  • 10Koo DH, Park SI, Kim YH, et al. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012;69(3):655-663. 被引量:1

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部